Spruce Biosciences Shares Quiet; Traders Circulate U.S. Patent Granted To Co Titled ‘Methods for treating testicular and ovarian adrenal rest tumors’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=11304950&OS=11304950&RS=11304950
Where Spruce Biosciences Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Spruce Biosciences (NASDAQ:SPRB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
SVB Leerink Maintains Market Perform on Spruce Biosciences, Lowers Price Target to $3
SVB Leerink analyst Joseph Schwartz maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Perform and lowers the price target from $5 to $3.
RBC Capital Maintains Outperform on Spruce Biosciences, Lowers Price Target to $9
RBC Capital analyst Gregory Renza maintains Spruce Biosciences (NASDAQ:SPRB) with a Outperform and lowers the price target from $13 to $9.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Avenue Therapeutics (NASDAQ:ATXI) stock moved upwards by 17.2% to $0.7 during Friday's after-market session. The company's market cap stands at $14.5 million.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
Avenue Therapeutics (NASDAQ:ATXI) stock increased by 17.2% to $0.7 during Thursday's after-market session. The company's market cap stands at $14.5 million.